Posts Tagged ‘Announces’

Targacept Announces Initiation Of Phase 2 Studies Of TC-6987 In Asthma And Type 2 Diabetes

Targacept Announces Initiation Of Phase 2 Studies Of TC-6987 In Asthma And Type 2 Diabetes
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes. TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor and was discovered by Targacept …

Read more on Medical News Today

Pepex announces development of combined glucose monitoring and insulin delivery meter

Pepex announces development of combined glucose monitoring and insulin delivery meter
Pepex Biomedical, Inc. has unveiled development of a next generation solution for insulin dependent diabetics which will combine regular glucose monitoring and insulin delivery for diabetes sufferers worldwide. The company is developing a complete product line of multi-function meters which allow simple testing of blood glucose levels and insulin delivery, appropriate to each glucose level …

Read more on News-Medical-Net

Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET

Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Santarus, Inc. , a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET® tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

Read more on Business Wire via Yahoo! Finance

FDA Announces It Will Significantly Restrict Access to the Diabetes Drug Avandia

FDA Announces It Will Significantly Restrict Access to the Diabetes Drug Avandia
The American Diabetes Association, the Endocrine Society and the American Association of Clinical Endocrinologists Joint Statement in Response to the FDA Decision to Restrict the Use of Avandia (rosiglitazone) in the U.S.

The Natural Hot Tub Company® Announces Natural Products for Spas and Hot Tubs

The Natural Hot Tub Company® Announces Natural Products for Spas and Hot Tubs
The words “green,” “healthy” and “hot tubs” have rarely been used in the same sentence in the past, but that’s changing because of a group of products that The Natural Hot Tub Company® is distributing. These enzyme-based products are so pure, no warning labels are required, and produce water that can be emptied from hot tubs directly onto lawns and trees, when cooled down with [PR.com]

Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp

Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp
ORLANDO, Fla., June 30 /PRNewswire/ — Novo Nordisk, a world leader in diabetes care, and Indy Lights race car driver Charlie Kimball today announced the availability of a wide array of resources to help kids with diabetes have a positive and rewarding summer camp experience. Kimball, who has type 1 diabetes, will hand out one of these resources today to attendees at the Children with Diabetes …

Tethys Announces Issuance Of Key Patent Relating To PreDx™ Diabetes Risk Score Test

Tethys Announces Issuance Of Key Patent Relating To PreDx™ Diabetes Risk Score Test
Tethys Bioscience, Inc., a privately held company, announced that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company’s groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition. Notably, this patent was issued following an …